Screener
Immunovant, Inc. IMVT EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026. Open the filing →
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
FAQ
- What is Immunovant, Inc.'s EPS (diluted)?
- Immunovant, Inc. (IMVT) reported EPS (diluted) of -$0.73 in Q1 2026.
- How has Immunovant, Inc.'s EPS (diluted) changed year-over-year?
- Immunovant, Inc.'s EPS (diluted) decreased by 15.9% year-over-year, from -$0.63 to -$0.73.
- What is the long-term trend for Immunovant, Inc.'s EPS (diluted)?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s EPS (diluted) has grown at a 18.1% compound annual growth rate (CAGR), from -$1.43 to -$2.78.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Immunovant, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude